Medical Oncology

Doç. Dr. Murad Gulıyev

Doctor and researcher Acıbadem Altunizade Hastanesi İstanbul

Breast NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsObesityCarcinoma, Renal CellKidney NeoplasmsStomach NeoplasmsCarcinoma, Transitional CellColorectal NeoplasmsNeoplasms

Open institution page

Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source

Breast Neoplasms 9 publications

Source: OpenAlex / PubMed MeSHView publications
Carcinoma, Non-Small-Cell Lung 4 publications
Lung Neoplasms 4 publications
Obesity 3 publications
Carcinoma, Renal Cell 3 publications
Kidney Neoplasms 3 publications
Stomach Neoplasms 2 publications
Carcinoma, Transitional Cell 2 publications
Colorectal Neoplasms 2 publications
Neoplasms 2 publications

Person ↔ Disease

Which topics does this doctor work on?

From source

Medical areas of interest stated by the doctor on the institution profile. Source: acibadem.com.tr.

Prostat Kanseri
Baş Boyun Kanserleri
Böbrek Kanseri
Karaciğer Kanseri
Mide Kanseri
Pankreas Kanseri
Akciğer, Akciğer Zarı Kanserleri (Mezotelyoma) ve Diğer Torasik Kanserler
Endometrial Kanser
Meme Kanseri
Kolorektal Kanserler (Kolon ve Rektum Kanseri)
Mesane Kanseri
Malign Melanom ve Diğer Deri Tümörleri
Akciğer Kanseri
Kolon (Kalın Bağırsak) Kanseri

Education and experience

From source

Experience

2026Doçent, Acıbadem Altunizade Hastanesiacibadem.com.tr
2024 - 2025Uzman Hekim, Yeni Yüzyıl Üniversitesi Özel Gaziosmanpaşa Hastanesiacibadem.com.tr
2021 - 2023Uzman Hekim, Acıbadem İnternational Hastanesiacibadem.com.tr
2020Acıbadem Sağlık Grubuacibadem.com.tr

Education

2025İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi, Tıbbi Onkoloji, Üst Uzmanlıkacibadem.com.tr
2025Avrupa (ESMO) Tıbbi Onkoloji Yeterlilik Sertifikası, Berlin, Almanya, Digeracibadem.com.tr
2021İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi, İç Hastalıkları, Uzmanlıkacibadem.com.tr
2015Azerbaycan Tıp Üniversitesi Tıp Fakültesi, Üniversiteacibadem.com.tr

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

SpecialtyMedical Oncologyacibadem.com.trFrom source
InstitutionAcıbadem Altunizade Hastanesiacibadem.com.trFrom source
Area of workBreast NeoplasmsExtracted from 9 publications · Model version —From source
Publications68 publicationsOpenAlexFrom source
Last synchronised4 November 2026 21:12https://www.acibadem.com.tr/doktor/murad-guliyev/acibadem.com.tr

Scientific work

Publications on Breast Neoplasms

68 publications

First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis

Medicina, 2026

DOI 10.3390/medicina62050984 PMID 42195237 Open-access full textSource: OpenAlex
Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

BMC Cancer, 2026

DOI 10.1186/s12885-026-16868-5 Open-access full textSource: OpenAlex
Comparative Prognostic Value of Systemic Inflammation-Based Biomarkers in Advanced Non-Small Cell Lung Cancer Treated with First-Line Immunotherapy

Biomedicines, 2026

DOI 10.3390/biomedicines14081825 PMID 42652206 Open-access full textSource: OpenAlex
Prognostic Impact of the Lung Immune Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab

Cancers, 2026

DOI 10.3390/cancers18071170 PMID 41976392 Open-access full textSource: OpenAlex
Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma

Immunotherapy, 2026

DOI 10.1080/1750743x.2026.2722548 PMID 42683510 Open-access full textSource: OpenAlex
Clinicopathological Predictors of Axillary Pathological Complete Response and Its Prognostic Significance in Clinically Node-Positive (cN+), HER2-Positive Breast Cancer Following Neoadjuvant Therapy

Medicina, 2026

DOI 10.3390/medicina62010200 PMID 41597486 Open-access full textSource: OpenAlex
Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab

Immunotherapy, 2026

DOI 10.1080/1750743x.2026.2662201 PMID 42011533 4 citations (Europe PMC) Open-access full textSource: OpenAlex
Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15041657 PMID 41753346 2 citations (Europe PMC) Open-access full textSource: OpenAlex
Prognostic Impact of PET/CT-Derived Sarcopenia in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15103736 PMID 42194697 1 citation (Europe PMC) Open-access full textSource: OpenAlex
Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study

Cancers, 2026

DOI 10.3390/cancers18132127 PMID 42449669 Open-access full textSource: OpenAlex

View all 68 publications

Other doctors working on these diseases

Memberships and more

Türk Tıbbi Onkoloji Derneği (TTOD)
American Society Of Medical Oncolog (ASCO)
European Society of Medical Oncology (ESMO)

Source: acibadem.com.tr

Ask Doctoria AI

Coming soon

In preparation for doctors, institutions and research teams. Examples of questions you will be able to ask:

Find the doctors with the most publications in Medical Oncology Find the researchers scientifically closest to this profile Find researchers for a multicentre study

Let’s improve this profile together

Every change is stored with its source, contributor and date.

Suggest a correction Add a publication Correct the institution Add a specialty Merge a duplicate record Claim profile

Last change: 64 yayın OpenAlex yazar kaydından eklendi Source: https://openalex.org/A5036621749
Contributor: Doctoria bot
Date: 5 November 2026 08:49